WO2015105522A1 - Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use - Google Patents

Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use Download PDF

Info

Publication number
WO2015105522A1
WO2015105522A1 PCT/US2014/028961 US2014028961W WO2015105522A1 WO 2015105522 A1 WO2015105522 A1 WO 2015105522A1 US 2014028961 W US2014028961 W US 2014028961W WO 2015105522 A1 WO2015105522 A1 WO 2015105522A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
antigen
region
car
receptor
Prior art date
Application number
PCT/US2014/028961
Other languages
English (en)
French (fr)
Inventor
Stephen J. Forman
Christine E. BROWN
Umamaheswararao JONNALAGADDA
Armen MARDIROS
Original Assignee
Forman Stephen J
Brown Christine E
Jonnalagadda Umamaheswararao
Mardiros Armen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15/111,384 priority Critical patent/US20160333108A1/en
Application filed by Forman Stephen J, Brown Christine E, Jonnalagadda Umamaheswararao, Mardiros Armen filed Critical Forman Stephen J
Priority to CA2936501A priority patent/CA2936501A1/en
Priority to AU2014376328A priority patent/AU2014376328A1/en
Priority to CN201480076612.7A priority patent/CN107074957B/zh
Priority to EP14877876.4A priority patent/EP3094653B1/de
Priority to EP19204610.0A priority patent/EP3626748A1/de
Priority to JP2016546921A priority patent/JP6560235B2/ja
Priority to ES14877876T priority patent/ES2767423T3/es
Publication of WO2015105522A1 publication Critical patent/WO2015105522A1/en
Priority to US16/221,257 priority patent/US20200040096A1/en
Priority to AU2020204351A priority patent/AU2020204351A1/en
Priority to US17/510,099 priority patent/US20220372164A1/en
Priority to AU2023203097A priority patent/AU2023203097A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Definitions

  • CAR chimeric antigen receptor
  • T cells can directly recognize and kill antigen-expressing tumor cells in a human leukocyte antigen (HLA)-independent manner.
  • HLA human leukocyte antigen
  • CARs that contain a TAA-specific scFv that produces an intracellular signal via a cytoplasmic costimulatory (e.g., CD28 or 4-1 BB) domain fused to CD3-zeta have been shown in various systems to exhibit significant antitumor potency (Brentjens et al. 2013; Brentjens et al. 201 1 ; Grupp et al. 2013; Kalos et al. 201 1 ; Kochenderfer et al. 2012), immunological rejection and clearance by the host remains a challenge to effective cancer treatment.
  • Certain modifications in CAR design have been used to prevent the FcR-mediated clearance of therapeutic cells.
  • hinge/spacer sequences that do not originate from Ig Fc domains may be used, such as those from CD8a or CD28 (Brentjens et al. 2007; Kalos et al. 201 1 ; Imai et al. 2004; Kochenderfer et al. 2009).
  • these spacer sequences may alleviate FcR binding, their length may not endow CAR T cells with optimal potency when targeting certain antigens. For instance, when targeting 5T4, NCAM and MUC1 using CAR T cells, longer linker regions (i.e., longer than those derived from CD8a or CD28) were required for optimal potency (Wilkie et al. 2008; Guest et al. 2005).
  • CAR chimeric antigen receptors having impaired binding to an Fc receptor
  • FcR Fc receptor
  • Such CARs may include, but are not limited to, an antigen recognition domain, a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR, and an intracellular signaling domain.
  • a population of human immune cells transduced by a viral vector comprising an expression cassette that includes a CAR gene is provided.
  • the CAR gene comprises a nucleotide sequence that encodes an antigen recognition domain, a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR, and an intracellular signaling domain, wherein the population of human immune cells expresses the CAR gene.
  • a method of treating a cancer in a subject is provided. Such a method includes administering a population of human immune cells transduced with a CAR gene to the subject.
  • the CAR gene comprises a nucleotide sequence that encodes an antigen recognition domain that targets a cancer associated antigen specific to the cancer, a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR, and an intracellular signaling domain.
  • Designing a CAR having a spacer domain that has decreased or impaired binding to FcRs helps prevent the FcR- expressing cells from recognizing and destroying, or unintentionally activating, the CAR-expressing immunotherapeutic cells in vivo. Therefore, such CARs help prevent immunological rejection and clearance of the cells meant to provide therapeutic benefit to patients
  • FIG. 1 shows that CD19-specific CAR-expressing T cells do not efficiently engraft in NSG mice according to one embodiment.
  • FIG. 1 a shows the schematics of the CD19R/EGFRt (top) and EGFRt (bottom) expression constructs that were used to gene modify T cells for engraftment studies.
  • FIG. 1 b is a flow cytometric analysis of T cells administered to NSG mice for engraftment studies.
  • TcM-derived cells were left non-transduced (Non-Txd), or were transduced with lentiviral vectors containing the CD19R/EGFRt (CD19R) or EGFRt/DHFRFS/IMPDH2IY (EGFRt) constructs described in (A) and immunomagnetically selected for EGFRt-expression.
  • the cells were then expanded in vitro for 19 days and analyzed for surface phenotype. Percentages of cells staining with antibodies specific for CD4 (top) or CD8 (bottom) vs. EGFRt are indicated in each histogram, using quadrants that were created based on negative control staining.
  • FIG. 2 illustrates that CD19-specific CAR-expressing T cells bind soluble FcyR1 according to one embodiment.
  • the same T cells described in FIG. 1 were stained with the indicated volume titration of biotinylated soluble human Fc gamma receptor 1 followed by PE-conjugated streptavidin (SA-PE, grey histogram).
  • SA-PE PE-conjugated streptavidin
  • percentages of immune reactive cells are indicated in each histogram, and based on an M 1 gate set to detect ⁇ 1 % of that stained with SA- PE alone (black line).
  • FIG. 3 shows that a mutated lgG4 spacer does not affect CD19- specific effector function of CAR-expressing T cells according to one embodiment.
  • FIG. 3a shows the schematics of the parental CD19-specific CAR (CD19R), the CD19-specific CAR that contains the 2 point mutations, L235E and N297Q, in the CH2 portion of the lgG4 spacer (CD19R(EQ)), and the CD19-specific CAR that contains a truncated lgG4 spacer, where the whole CH2 domain is removed (CD19Rch2A).
  • TcM-derived, EGFRt-enriched and expanded cells expressing either the parental CD19R, the EGFRt marker alone, the CD19R that has a single lgG4 point mutation at either amino acid 235 (CD19R(L235E)) or amino acid 297 (CD19R(N297Q)), the double- mutated CD19R(EQ) or the CH2-deleted CD19Rch2A were analyzed for transgene expression.
  • Percentages of cells staining with antibodies specific for the Fc- containing CAR (top) or EGFRt (bottom) are indicated in each histogram, and based on an M 1 gate set to detect ⁇ 1 % of that stained with SA-PE alone (black line).
  • FIG. 3c the same cells used in FIG. 3b were used as effectors in a 4-hour chromium release assay against 51 Cr-labeled CD19 + LCL or SupB15 targets.
  • LCL expressing the CD3 agonist OKT3 (LCL-OKT3) and CD19-negative K562 cells were used as positive- and negative-control targets, respectively.
  • Mean percent chromium release + S.D. of triplicate wells at the indicated E:T ratios are depicted.
  • FIG. 4 shows that CARs with a mutated lgG4 spacer exhibit inhibited FcyR binding according to one embodiment.
  • TCM-derived, EGFRt-enriched, expanded cell lines expressing either the EGFRt marker alone, the parental CD19R, the single point-mutated CD19R(L235E) or CD19R(N297Q), the double point- mutated CD19R(EQ), or the CH2-deleted CD19Rch2A were stained with the following biotinylated reagents: anti-Fc antibody (to detect the CAR), cetuximab (to detect EGFRt), or the indicated human (Hu) or murine (Mu) soluble Fc receptors (FcyR1 , R2a, or R2b); followed by PE-conjugated streptavidin (SA-PE, grey histogram). Percentages of immune reactive cells are indicated in each histogram, and based on an M1 gate set to detect ⁇ 1 % of that stained
  • FIG. 5 shows that T cells expressing CARs with mutated lgG4 spacer exhibit enhanced in vivo engraftment according to one embodiment.
  • 10 7 Tc M -derived, EGFRt-enriched cells expressing either the parental CD19R, the EGFRt marker alone, the single point-mutated CD19R(L235E) or CD19R(N297Q), the double point- mutated CD19R(EQ), or the CH2-deleted CD19Rch2A (see phenotype FIG. 3b) were infused i.v. into NSG mice on day 0 with irradiated NS0-IL15 support.
  • FIG. 5a mean percentages of CD45+ EGFRt+ cells in the viable lymphocyte-gated population +S.E.M. are indicated. *, p ⁇ 0.034 when compared to mice given CD19R-expressing cells using an unpaired Student's t-test.
  • FIG. 5b shows representative histograms (i.e., median 3 of each group of 5 mice) that are depicted with quadrants created based on control staining. Percentages of huCD45+ EGFRt+ cells are indicated in each histogram.
  • FIG. 6 shows that Tc M -derived cells expressing CARs with mutated lgG4 spacer exhibit enhanced therapeutic efficacy according to some embodiments.
  • 1 .5 x 10 6 ffl_uc + LCL cells were administered i.v. into NSG mice on day 0, and then 5 x 10 6 CAR+ Tc M -derived cells (10 7 cells total) expressing either the EGFRt marker alone, the parental CD19R, the double point-mutated CD19R(EQ), or the CH2- deleted CD19Rch2A were infused i.v. into NSG mice on day 3.
  • LCL tumor growth was then monitored by Xenogen imaging.
  • FIG. 6a shows a flow cytometric analysis depicting the CAR profiles of the input Tc M -derived cells (used at day 23 after bead stimulation and lentitransduction). Percentages of immunoreactive cells are indicated in each histogram, and based on an M 1 gate set to detect ⁇ 1 % of that stained with SA-PE alone (black line).
  • FIG. 6c shows representative bioluminescence images of NSG mice at day 21 are depicted for each group.
  • FIG. 6d shows mean percentages (+ S.E.M.) of CD45 + EGFRt + cells in the viable lymphocyte-gated population of peripheral blood at day 21 are indicated. *, p ⁇ 0.035 when compared to mice given CD19R-expressing cells using an unpaired Student's t-test.
  • FIG. 7 shows that bulk T cells expressing CD19R(EQ) exhibit enhanced therapeutic efficacy according to one embodiment.
  • 1 .5 x 10 6 ffl_uc + LCL cells were administered i.v. into NSG mice on day 0, and then 5 x 10 6 CAR + T cells expressing either the parental CD19R or the double point-mutated CD19R(EQ) were infused i.v. into NSG mice on day 2.
  • LCL tumor growth was then monitored by Xenogen imaging.
  • FIG. 7a shows a flow cytometric analysis of the CAR (top), EGFRt vs.
  • CD3 (middle) and CD4 vs CD8 (bottom) profiles of the input T cells (used at day 21 after bead stimulation and lentitransduction). Percentages of immunoreactive cells as determined by histogram subtraction (top), or based on quadrants that were drawn according to the staining of mock-transduced cells and isotype control staining (middle, bottom) are depicted in each histogram.
  • FIG. 7b shows representative bioluminescence images of NSG mice at day 2, 1 1 and 23 are depicted for each group.
  • FIG. 8 shows that non-enriched TcM-derived cells expressing CARs with mutated lgG4 spacer exhibit enhanced in vivo engraftment according to some embodiments.
  • 10 7 TcM-derived cells expressing either the EGFRt marker alone, the parental CD19R, or the double point-mutated CD19R(EQ) were infused i.v. into NSG mice on day 0 with irradiated NS0-IL15 support.
  • FIG. 8A shows a flow cytometric analysis depicting the CAR profiles of the input TcM-derived cells (used at day 26 after bead stimulation and lentitransduction). Percentages of cells staining with antibodies specific for the Fc- containing CAR (top) or EGFRt (bottom) are indicated in each histogram, and based on an M 1 gate set to detect 1 % of that stained with SA-PE alone (black line).
  • FIG. 8B shows mean percentages of CD45+EGFRt+ cells in the viable lymphocyte-gated population ⁇ S.E.M. are indicated.
  • FIG. 8C shows representative histograms (i.e., median 2 of each group of 4-6 mice) are depicted with quadrants created based on control staining. Percentages of huCD45+ EGFRt+ cells are indicated in each histogram.
  • a CAR may include a series of protein or peptide domains including, but not limited to, one or more of an antigen binding domain, a spacer domain, a transmembrane domain, an intracellular signaling domain and an intracellular costimulatory domain.
  • a gene encoding the CAR is provided, wherein the gene includes a nucleotide or nucleic acid sequence which includes a series of regions which encode an amino acid sequence corresponding to the protein or peptide domains of the CAR described herein. Because the degeneracy of the genetic code is known, any amino acid sequences disclosed herein are also indicative of all degenerate nucleic acid codons corresponding to each amino acid in said sequences. As such, it is understood that the embodiments describing CARs and their domains may be provided as a gene comprising a nucleic acid sequence as well as the amino acid sequences encoded by said genes.
  • a CAR may include, but is not limited to, an antigen binding domain, a spacer domain, optionally at least one intracellular signaling domain and optionally at least one intracellular costimulatory domain.
  • a CAR may include, but is not limited to, an antigen binding domain, a spacer domain, and at least one intracellular signaling domain.
  • a CAR may include, but is not limited to, an antigen binding domain, a spacer domain, at least one intracellular signaling domain and at least one intracellular costimulatory domain.
  • a CAR antigen binding domain may include a nucleotide sequence that, when expressed as a peptide or polypeptide, binds an epitope of a cancer- related antigen.
  • a cancer-related antigen may be any antigen expressed by or overexpressed by a cancer cell (e.g., a tumor cell, a neoplastic cell, a malignant cell, or any other cancerous cell), and may be a protein, peptide, carbohydrate, glycoprotein, ganglioside, proteoglycan, or any combination or complex thereof.
  • the cancer-related antigen is a tumor specific antigen (TSA) that may be expressed only on cancer or tumor cells, while in other aspects, the cancer-related antigen is a tumor-associated antigen (TAA) that may be expressed on both tumor cells and normal cells.
  • TSA tumor specific antigen
  • TAA tumor-associated antigen
  • the cancer-related antigen may be a product of a mutated oncogene or tumor suppressor gene, or a product of another mutated gene (e.g., overexpressed or aberrantly expressed cellular proteins, tumor antigens produced by oncogenic viruses, oncofetal antigens, altered cell surface glycolipids or glycoproteins, or cell type-specific differentiation antigens).
  • cancer-related antigens that may be targeted by a CAR antigen binding domain described herein include, but are not limited to, 5T4, 8H9, ⁇ ⁇ ⁇ integrin, alphafetoprotein (AFP), B7- H6, CA-125 carbonic anhydrase 9 (CA9), CD19, CD20, CD22, CD30, CD33, CD38, CD44, CD44v6, CD44v7/8, CD52, CD123, CD171 , carcionoembryonic antigen (CEA), EGFrvlll, epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP- 40), ErbB1/EGFR, ErbB2/HER2/neu/EGFR2, ErbB3, ErbB4, epithelial tumor antigen (ETA), FBP, fetal acetylcholine receptor (AchR), folate receptor-a, G250/CAIX, ganglioside 2 (GD2),
  • CEA carcionoembryonic antigen
  • mucin-16 MUC16
  • NCAM nerve cell adhesion molecule
  • NY-ESO-1 Oncofetal antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), receptor-tyrosine kinase-like orphan receptor 1 (ROR1 ), TAA targeted by mAb IgE, tumor-associated glycoprotein-72 (TAG-72), tyrosinase, and vascular endothelial growth factor (VEGF) receptors.
  • the antigen binding domain that is part of a CAR described herein targets CD19 or CD123.
  • an antigen binding domain may be any targeting moiety which targets an antigen associated with cancer.
  • the antigen binding domain is an antibody or functional fragment of an antibody.
  • An antibody refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive with an antigen or epitope, and includes both polyclonal and monoclonal antibodies, as well as functional antibody fragments, including but not limited to fragment antigen binding (Fab) fragments, F(ab')2 fragments, Fab' fragments, Fv fragments, recombinant IgG (rlgG) fragments, single chain variable fragments (scFv) and single domain antibodies (e.g., sdAb, sdFv, nanobody) fragments.
  • Fab fragment antigen binding
  • antibody or functional fragment thereof also includes genetically engineered or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies (e.g., bispecific antibodies, diabodies, triabodies, tetrabodies, tandem di- scFv, tandem tri-scFv). Unless otherwise stated, the term “antibody” should be understood to encompass functional antibody fragments thereof.
  • the antigen binding domain is an scFv having a heavy (V H ) and light chain (V L ).
  • the antigen binding domain is an scFv that targets CD19 or CD123.
  • the scFv that targets CD19 may have the following amino acid sequence:
  • scFv that targets CD123 may have one of the following amino acid sequences:
  • the spacer domain (also referred to as a "hinge region” or “spacer/hinge region”) may be derived from or include at least a portion of an immunoglobulin Fc region, for example, an lgG1 Fc region, an lgG2 Fc region, an lgG3 Fc region, an lgG4 Fc region, an IgE Fc region, an IgM Fc region, or an IgA Fc region.
  • an immunoglobulin Fc region for example, an lgG1 Fc region, an lgG2 Fc region, an lgG3 Fc region, an lgG4 Fc region, an IgE Fc region, an IgM Fc region, or an IgA Fc region.
  • the spacer domain includes at least a portion of an lgG1 , an lgG2, an lgG3, an lgG4, an IgE, an IgM, or an IgA immunoglobulin Fc region that falls within its CH2 and CH3 domains.
  • the spacer domain may also include at least a portion of a corresponding immunoglobulin hinge region.
  • the spacer domain is derived from or includes at least a portion of a modified immunoglobulin Fc region, for example, a modified lgG1 Fc region, a modified lgG2 Fc region, a modified lgG3 Fc region, a modified lgG4 Fc region, a modified IgE Fc region, a modified IgM Fc region, or a modified IgA Fc region.
  • the modified immunoglobulin Fc region may have one or more mutations (e.g., point mutations, insertions, deletions, duplications) resulting in one or more amino acid substitutions, modifications, or deletions that cause impaired binding of the spacer domain to an Fc receptor (FcR).
  • the modified immunoglobulin Fc region may be designed with one or more mutations which result in one or more amino acid substitutions, modifications, or deletions that cause impaired binding of the spacer domain to one or more FcR including, but not limited to, FcyRI, FcyR2A, FcyR2B1 , FcyR2B2, FcyR3A, FcyR3B, FccRI, FccR2, FcaRI, Fca ⁇ R, or FcRn.
  • FcyRI FcyR2A
  • FcyR2B1 FcyR2B2
  • FcyR3A FcyR3B
  • FccRI FccR2
  • FcaRI Fca ⁇ R
  • FcRn FcRn
  • FcRs such as FcyRI
  • NK natural killer cells
  • macrophages which then use this Fc-targeting ability to carry out various immune functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • Impairment of binding to FcRs by the spacer domain prevents the FcR- expressing cells from recognizing and destroying, or unintentionally activating, the CAR-expressing immunotherapeutic cells in vivo, thereby helping to prevent immunological rejection and clearance of the cells meant to provide therapeutic benefit to patients.
  • the mutations described herein also contribute to reducing the CAR's off-target effects and , thereby increasing its specificity and efficacy.
  • amino acid modification or an “amino acid substitution” or a “substitution,” as used herein, mean an amino acid substitution, insertion, and/or deletion in a protein or peptide sequence.
  • amino acid substitution or “substitution” as used herein, means a replacement of an amino acid at a particular position in a parent peptide or protein sequence with another amino acid.
  • substitution S228P refers to a variant protein or peptide, in which the serine at position 228 is replaced with proline.
  • Amino acid substitutions can be made by a mutation such that a particular codon in the nucleic acid sequence encoding the protein or peptide is changed to a codon which codes for a different amino acid. Such a mutation is generally made by making the fewest nucleotide changes possible.
  • a substitution mutation of this sort can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to the same grouping).
  • a conservative change generally leads to less change in the structure and function of the resulting protein.
  • Amino acids with nonpolar R groups Alanine, Valine, Leucine, Isoleucine, Proline, Phenylalanine, Tryptophan, Methionine.
  • Amino acids with uncharged polar R groups Glycine, Serine, Threonine, Cysteine, Tyrosine, Asparagine, Glutamine.
  • Amino acids with charged polar R groups (negatively charged at Ph 6.0): Aspartic acid, Glutamic acid.
  • Another grouping may be those amino acids with phenyl groups: Phenylalanine, Tryptophan, Tyrosine.
  • Another grouping may be according to molecular weight (i.e., size of R groups) as shown below:
  • the spacer domain is derived from a modified lgG1 , lgG2, lgG3, or lgG4 Fc region that includes one or more amino acid residues substituted with an amino acid residue different from that present in an unmodified hinge.
  • the one or more substituted amino acid residues are selected from, but not limited to one or more amino acid residues at positions 220, 226, 228, 229, 230, 233, 234, 235, 234, 237, 238, 239, 243, 247, 267, 268, 280, 290, 292, 297, 298, 299, 300, 305, 309, 218, 326, 330, 331 , 332, 333, 334, 336, 339, or a combination thereof.
  • the spacer domain is derived from a modified lgG1 , lgG2, lgG3, or lgG4 Fc region that includes, but is not limited to, one or more of the following amino acid residue substitutions: C220S, C226S, S228P, C229S, P230S, E233P, V234A, L234V, L234F, L234A, L235A, L235E, G236A, G237A, P238S, S239D, F243L, P247I, S267E, H268Q, S280H, K290S, K290E, K290N, R292P, N297A, N297Q, S298A, S298G, S298D, S298V, T299A, Y300L, V305I, V309L, E318A, K326A, K326W, K326E, L328F
  • the spacer domain is derived from an IgG Fc region having one or more modifications made to its CH2-CH3 region, wherein the unmodified IgG CH2-CH3 region corresponds to one of the following amino acid sequences:
  • the spacer domain is derived from an IgG Fc region having one or more modifications made to its hinge region, wherein the unmodified IgG hinge region corresponds to one of the following amino acid sequences:
  • IgG2 ERKCCVECPPCP SEQ ID NO : 12
  • IgG4 ESKYGPPCPSCP (SEQ ID NO : 14 )
  • the spacer domain is derived from an lgG4 region having the following amino acid sequence:
  • the spacer domain is derived from a modified lgG4 Fc that includes one or more amino acid residues substituted with an amino acid residue different from that present in an unmodified lgG4 Fc region.
  • the one or more substituted amino acid residues are selected from, but not limited to one or more amino acid residues at positions 220, 226, 228, 229, 230, 233, 234, 235, 234, 237, 238, 239, 243, 247, 267, 268, 280, 290, 292, 297, 298, 299, 300, 305, 309, 218, 326, 330, 331 , 332, 333, 334, 336, 339, 396, or a combination thereof.
  • the spacer domain is derived from a modified lgG4 Fc region that includes, but is not limited to, one or more of the following amino acid residue substitutions: 220S, 226S, 228P, 229S, 230S, 233P, 234A, 234V, 234F, 234A, 235A, 235E, 236A, 237A, 238S, 239D, 243L, 247I, 267E, 268Q, 280H, 290S, 290E, 290N, 292P, 297A, 297Q, 298A, 298G, 298D, 298V, 299A, 300L, 305I, 309L, 318A, 326A, 326W, 326E, 328F, 330L, 330S, 331 S, 331 S, 332E, 333A, 333S, 333S, 334A, 339D, 339Q, 396L
  • the spacer domain is derived from a modified lgG4 Fc region that includes, but is not limited to, two or more (i.e., "double mutated"), three or more (i.e., "triple mutated"), four or more, five or more, or more than five of the following amino acid residue substitutions: 220S, 226S, 228P, 229S, 230S, 233P, 234A, 234V, 234F, 234A, 235A, 235E, 236A, 237A, 238S, 239D, 243L, 247I, 267E, 268Q, 280H, 290S, 290E, 290N, 292P, 297A, 297Q, 298A, 298G, 298D, 298V, 299A, 300L, 305I, 309L, 318A, 326A, 326W, 326E, 328F, 330L,
  • the spacer domain is derived from a modified lgG4 Fc region that includes, but is not limited to, a substitution of proline (P) in place of serine (S) at position 228 (S228P), a substitution of leucine (L) in place of glutamic acid (E) at position 235 (L235E), a substitution of asparagine (N) in place of glutamine (Q) at position 297 (N297Q), or a combination thereof.
  • a modified lgG4 Fc region has a single mutation, as indicated in the following amino acid sequences (mutations are in bold and underlined):
  • ESKYGPPCPS CPAPEFEGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSS IEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK ( L235E mutation ; SEQ ID NO : 16 )
  • the spacer domain is derived from a modified lgG4 Fc region that is double mutated to include an L235E substitution and an N297Q substitution ("EQ").
  • the modified lgG4 Fc region is triple mutated to include an S228P substitution, an L235E substitution, and an N297Q substitution ("S228P+L235E+N297Q").
  • a modified lgG4 Fc and/or hinge region may include a nucleotide sequence which encodes an amino acid sequence selected from the following (mutations are in bold and underlined):
  • ESKYGPPCPS CPAPEFEGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFQS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSS IEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK (EQ mutation ; SEQ ID NO : 18 )
  • the spacer domain is derived from a modified immunoglobulin Fc region that includes one or more deletions of all of a part of its CH2 domain.
  • the spacer domain is derived from a modified lgG4 Fc region that includes one or more deletions of all of a part of its CH2 domain ("ch2A").
  • the spacer domain may include a nucleotide sequence which encodes the following amino acid sequence:
  • ESKYGPPCPP CPGGGSSGGG SGGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK ( ch2 ⁇ mutation/deletion ; SEQ I D NO : 20 )
  • the spacer domain may be modified to substitute the immunoglobulin Fc region for a spacer that does not have the ability to bind FcR, such as the hinge region of CD8a.
  • the Fc spacer region of the hinge may be deleted. Such substitutions would reduce or eliminate Fc binding.
  • position is a location in the sequence of a protein. Positions may be numbered sequentially, or according to an established format, for example a Kabat position or an EU position or EU index as in Kabat. For all positions discussed herein, numbering is according to the EU index or EU numbering scheme (Kabat et al., 1991 , Sequences of Proteins of Immunological Interest, 5th Ed., United States Public Health Service, National Institutes of Health, Bethesda, hereby entirely incorporated by reference).
  • the EU index or EU index as in Kabat or EU numbering scheme refers to the numbering of the EU antibody (Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85, which is hereby entirely incorporated by reference).
  • Kabat positions while also well known in the art, may vary from the EU position for a given position.
  • the S228P and L235E substitutions described above refer to the EU position.
  • these substitutions may also correspond to Kabat positions 241 (S241 P) and 248 (L248E).
  • the intracellular signaling domain may include any suitable T cell receptor (TCR) complex signaling domain, or portion thereof.
  • TCR T cell receptor
  • the intracellular signaling domain is derived from a CD3 complex.
  • the intracellular signaling domain is a TCR zeta-chain ( ⁇ -chain) signaling domain.
  • a ⁇ -chain signaling domain may include a nucleotide sequence which encodes an amino acid sequence as follows:
  • the intracellular signaling domain may be associated with any suitable costimulatory domain including, but not limited to, a 4-1 BB costimulatory domain, an OX-40 costimulatory domain, a CD27 costimulatory domain, a CD28 costimulatory domain, a DAP10 costimulatory domain, an inducible costiumulatory (ICOS) domain, or a 2B4 costimulatory domain.
  • a CAR may include at least one costimulatory signaling domain.
  • the CAR has a single costimulatory signaling domain, or it may include two or more costimulatory signaling domains such as those described above.
  • the costimulatory domain may be made up of a single costimulatory domain such as those described above, or alternatively, may be made up of two or more portions of two or more costimulatory domains.
  • the CAR does not include a costimulatory signaling domain.
  • the CAR includes a costimulatory signaling domain which is a CD28 costimulatory domain.
  • such a modified CD28 costimulatory domain may have one or more amino acid substitutions or modifications including, but not limited to a substitution of leucine-leucine (LL) to glycine-glycine (GG).
  • a modified costimulatory signaling domain region may include a nucleotide sequence which encodes an amino acid sequence selected from the following:
  • the signaling domain or domains may include a transmembrane domain selected from a CD28 transmembrane domain, a CD3 transmembrane domain, or any other suitable transmembrane domain known in the art.
  • the transmembrane domain is a CD28 transmembrane domain.
  • a modified costimulatory signaling domain region may include a nucleotide sequence which encodes an amino acid sequence selected from the following:
  • the CAR gene is part of an expression cassette.
  • the expression cassette may - in addition to the CAR gene - also include an accessory gene.
  • the accessory gene When expressed by a T cell, the accessory gene may serve as a transduced T cell selection marker, an in vivo tracking marker, or a suicide gene for transduced T cells.
  • the accessory gene is a truncated EGFR gene (EGFRt).
  • EGFRt may be used as a non-immunogenic selection tool (e,g., immunomagnetic selection using biotinylated cetuximab in combination with anti- biotin microbeads for enrichment of T cells that have been lentivirally transduced with EGFRt-containing constructs), tracking marker (e.g., flow cytometric analysis for tracking T cell engraftment), and suicide gene (e.g., via Cetuximab/Erbitux® mediated antibody dependent cellular cytotoxicity (ADCC) pathways).
  • ADCC Cetuximab/Erbitux® mediated antibody dependent cellular cytotoxicity
  • EGFRt truncated EGFR
  • the accessory gene is a truncated CD19 gene (CD19t).
  • the accessory gene is an inducible suicide gene.
  • a suicide gene is a recombinant gene that will cause the cell that the gene is expressed in to undergo programmed cell death or antibody mediated clearance at a desired time.
  • an inducible suicide gene that may be used as an accessory gene is an inducible caspase 9 gene (see Straathof et al. (2005). An inducible caspase 9 safety switch for T-cell therapy. Blood. June 1 ; 105(1 1 ): 4247- 4254, the subject matter of which is hereby incorporated by reference as if fully set forth herein).
  • the expression cassette that include a CAR gene described above may be inserted into a vector for delivery - via transduction or transfection - of a target cell.
  • Any suitable vector may be used, for example, a bacterial vector, a viral vector, or a plasmid.
  • the vector is a viral vector selected from a retroviral vector, a lentiviral vector, a poxvirus vector, an adenoviral vector, or an adeno-associated viral vector.
  • the vector may transduce a population of healthy immune cells, e.g., T cells. Successfully transduced or transfected target cells express the one or more genes that are part of the expression cassette.
  • one or more populations of immune cells may be transduced with a CAR gene such as those described above.
  • the transduced T cells may be from a donor, or may be from a subject having a cancer and who is in need of a treatment for the cancer.
  • the transduced T cells are used in an adoptive immunotherapy treatment for the treatment of the cancer (residues in bold/underline indicate substitutions).
  • the transduced T cells express a CAR gene that encodes an amino acid sequence selected from SEQ ID NOS:24-27:
  • CD19R (N297Q) 28 Z SEQ ID NO : 25 )
  • CD19R (EQ) 28 Z SEQ ID NO : 26 )
  • CD19RCH2ACD28 Z ( SEQ I D NO : 27 )
  • the one or more populations of T cells may be part of a pharmaceutically acceptable composition for delivery for administration to a subject.
  • the pharmaceutically effective composition may include one or more pharmaceutically effective carriers.
  • a "pharmaceutically acceptable carrier” as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a treatment of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body.
  • Such a carrier may comprise, for example, a liquid, solid, or semi-solid filler, solvent, surfactant, diluent, excipient, adjuvant, binder, buffer, dissolution aid, solvent, encapsulating material, sequestering agent, dispersing agent, preservative, lubricant, disintegrant, thickener, emulsifier, antimicrobial agent, antioxidant, stabilizing agent, coloring agent, or some combination thereof.
  • Each component of the carrier is "pharmaceutically acceptable" in that it must be compatible with the other ingredients of the composition and must be suitable for contact with any tissue, organ, or portion of the body that it may encounter, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.
  • Some examples of materials which can serve as pharmaceutically- acceptable carriers include: (1 ) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) natural polymers such as gelatin, collagen, fibrin, fibrinogen, laminin, decorin, hyaluronan, alginate and chitosan; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (1 1 ) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12)
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • the pharmaceutically acceptable carrier is an aqueous carrier, e.g. buffered saline and the like.
  • the pharmaceutically acceptable carrier is a polar solvent, e.g. acetone and alcohol.
  • the concentration of CAR-transduced T cells in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, organ size, body weight and the like in accordance with the particular mode of administration selected and the biological system's needs.
  • populations of T cells transduced with a CAR gene such as those described herein cells used in the methods for targeting and killing cancer or tumor cells may be grown in a cell culture.
  • the method may be used in an in vitro or research setting to investigate the role of a particular cancer-related antigen in the etiology of a cancer, or to evaluate the targeting abilities of new CAR constructs.
  • CAR genes and populations of T cells that are transduced with CAR genes such as those described above may be used in methods for treating cancer in a subject. Such methods may include a step of administering a therapeutically effective amount of at least one population of T cells transduced with at least one CAR gene to the subject.
  • the population of CAR-transduced T-cells expresses one or more CAR genes, such as those described above.
  • the T cells are transduced with and express a single mutant gene construct such as a CD19R(L235E) or CD19R(N297Q) construct as described herein, a double mutant gene construct which has both a L235E and N297Q mutation (e.g., CD19R(EQ)), as described herein, or a deletion gene construct (e.g., CD19Rch2A), as described herein.
  • a single mutant gene construct such as a CD19R(L235E) or CD19R(N297Q) construct as described herein
  • a double mutant gene construct which has both a L235E and N297Q mutation e.g., CD19R(EQ)
  • a deletion gene construct e.g., CD19Rch2A
  • Cancers that may be treated using the population of transduced T cells may include, but are not limited to, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Adrenocortical, Carcinoma, AIDS-Related Cancers, Anal Cancer, Appendix Cancer, Astrocytomas, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System, Basal Cell Carcinoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Osteosarcoma and Malignant Fibrous Histiocytoma, Brain Stem Glioma, Brain Tumors, Breast Cancer, Bronchial Tumors, Burkitt Lymphoma, Carcinoid Tumors, Central Nervous System Cancers, Cervical Cancer, Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Chronic Myeloproliferative Disorders, Colon Cancer, Colorectal
  • the population or populations of T cells transduced with the CAR gene or genes that may be used in accordance with the methods described herein may be administered, by any suitable route of administration, alone or as part of a pharmaceutical composition.
  • a route of administration may refer to any administration pathway known in the art, including but not limited to intracranial, parenteral, or transdermal.
  • Parenter refers to a route of administration that is generally associated with injection, including infraorbital, infusion, intraarterial, intracapsular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intratumoral, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal.
  • transduced T cells are administered intravenously or intrathecally.
  • an effective amount refers to an amount of an agent, compound, treatment or therapy that produces a desired effect.
  • a population of cells may be contacted with an effective amount of an agent, compound, treatment or therapy to study its effect in vitro (e.g., cell culture) or to produce a desired therapeutic effect ex vivo or in vitro.
  • An effective amount of an agent, compound, treatment or therapy may be used to produce a therapeutic effect in a subject, such as preventing or treating a target condition, alleviating symptoms associated with the condition, or producing a desired physiological effect.
  • the effective amount of a compound is a "therapeutically effective amount,” “therapeutically effective concentration” or “therapeutically effective dose.”
  • the precise effective amount or therapeutically effective amount is an amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given subject or population of cells. This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the compound (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication) or cells, the nature of the pharmaceutically acceptable carrier or carriers in the formulation, and the route of administration.
  • an effective or therapeutically effective amount may vary depending on whether the compound is administered alone or in combination with another compound, drug, therapy or other therapeutic method or modality.
  • One skilled in the clinical and pharmacological arts will be able to determine an effective amount or therapeutically effective amount through routine experimentation, namely by monitoring a cell's or subject's response to administration of a compound and adjusting the dosage accordingly.
  • Remington The Science and Practice of Pharmacy, 21 st Edition, Univ. of Sciences in Philadelphia (USIP), Lippincott Williams & Wilkins, Philadelphia, PA, 2005, which is hereby incorporated by reference as if fully set forth herein.
  • Agents, compounds treatments or therapies that may be used in an effective amount or therapeutically effective amount to produce a desired effect in accordance with the embodiments described herein may include, but are not limited to, a CAR gene, an expression cassette that includes a CAR gene, a vector that delivers an expression cassette that includes a CAR gene to a target cell such as a T cell, and a population of T cells that are transduced with a CAR gene.
  • treating may refer to preventing the condition, slowing the onset or rate of development of the condition, reducing the risk of developing the condition, preventing or delaying the development of symptoms associated with the condition, reducing or ending symptoms associated with the condition, generating a complete or partial regression of the condition, or some combination thereof.
  • Treatment may also mean a prophylactic or preventative treatment of a condition.
  • subject refers to a human or animal, including all mammals such as primates (particularly higher primates), sheep, dog, rodents (e.g., mouse or rat), guinea pig, goat, pig, cat, rabbit, and cow. In some embodiments, the subject is a human.
  • the methods for treating cancer may include a step of administering a therapeutically effective amount of a first population of T cells transduced with a first CAR gene in combination with a therapeutically effective amount of a second population of T cells transduced with a second CAR gene.
  • CAR-transduced T cells may be administered in combination with one or more additional anti-cancer therapies.
  • “In combination” or “in combination with,” as used herein, means in the course of treating the same cancer in the same subject using two or more agents, drugs, therapeutics, procedures, treatment regimens, treatment modalities or a combination thereof, in any order. This includes simultaneous administration, as well as in a temporally spaced order of up to several days apart.
  • Such combination treatment may also include more than a single administration of any one or more of the agents, drugs, therapeutics, procedures, treatment regimens, and treatment modalities.
  • the administration of the two or more agents, drugs, therapeutics, procedures, treatment regimens, treatment modalities or a combination thereof may be by the same or different routes of administration.
  • Additional anti-cancer therapies may include one or more anti-cancer procedures, treatment modalities, anti-cancer therapeutics or a combination thereof.
  • the CAR-transduced T cells may be administered in combination with one or more anti-cancer procedures or treatment modalities including, but not limited to, stem cell transplantation (e.g., bone marrow transplant or peripheral blood stem cell transplant using allogenic stem cells, autologous stem cells; or a non- myeloablative transplant), radiation therapy, or surgical resection.
  • stem cell transplantation e.g., bone marrow transplant or peripheral blood stem cell transplant using allogenic stem cells, autologous stem cells; or a non- myeloablative transplant
  • radiation therapy e.g., radiation therapy, or surgical resection.
  • the CAR-transduced T cells may be administered in combination with one or more anti-cancer therapeutics or drugs that may be used to treat cancer including, but not limited to, chemotherapeutics and other anti-cancer drugs, immunotherapeutics, targeted therapeutics, or a combination thereof.
  • Chemotherapeutics and other anti-cancer drugs that may be administered in combination with the CAR-transduced T cells in accordance with the embodiments described herein include, but are not limited to, all-trans-retinoic acid (ATRA), arsenic trioxide, anthracycline antibiotics and pharmaceutically acceptable salts thereof (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, idarubicin, mitoxantrone), alkylating agents (e.g., cyclophosphamide, laromustine), antimetabolite analogs (cytarabine, 6-thioguanine, 6-mercaptopuhne, methotrexate), demethylating agents (e.g., decitabine, 5-azacytidine), nucleic acid synthesis inhibitors (e.g., hydroxyurea), topoisomerase inhibitors (e.g., etoposide), vinca alkaloids (e.g.
  • Immunotherapeutics that may be administered in combination with the CAR-transduced T cells in accordance with the embodiments described herein include, but are not limited to, immune modulatory reagents (e.g., STAT3 inhibitors, Lenalidomide) and therapeutic monoclonal antibodies.
  • immune modulatory reagents e.g., STAT3 inhibitors, Lenalidomide
  • therapeutic monoclonal antibodies may be designed to target one or more additional cancer-related antigens
  • Targeted therapeutics that may be administered in combination with the CAR-transduced T cells in accordance with the embodiments described herein include, but are not limited to, tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, sunitinib), farnesyl transferase inhibitors (e.g., tipifarnib), FLT inhibitors, and c-Kit (or CD1 17) inhibitors (imatinib, dasatinib, nilotinib).
  • tyrosine kinase inhibitors imatinib, dasatinib, nilotinib, sunitinib
  • farnesyl transferase inhibitors e.g., tipifarnib
  • FLT inhibitors e.g., tipifarnib
  • c-Kit (or CD1 17) inhibitors imatinib, dasatinib, nilotinib
  • Example 1 Chimeric Antigen Receptors (CARs) Incorporating Mutations in the lgG4 Fc Spacer Region Avoid Fc Receptor Mediated Recognition and Clearance of CAR T Cells, Resulting in Improved T cell Persistence and Anti- Tumor Efficacy
  • CD19-specific CAR that has been mutated at one or two sites within the CH2 region (L235E and/or N297Q) of its lgG4 Fc spacer - referred to herein as CD19R(L235E), CD19R(N297Q) or CD19R(EQ) - as well as a CD19-specific CAR that has a CH2 deletion in its lgG4 Fc spacer - referred to herein as CD19Rch2A.
  • T cells expressing these mutated CAR were then compared to T cells expressing a non-mutated CAR (CD19R) or only a truncated EGFR molecule (EGFRt) as a tracking marker (Wang et al. 201 1 ), for in vitro FcyR binding and CAR- mediated cytolytic activity, as well as in vivo engraftment and therapeutic efficacy.
  • CD19R non-mutated CAR
  • EGFRt truncated EGFR molecule
  • the CD19R28Z-T2A- EGFRt_epHIV7 lentiviral construct contains a) the chimeric antigen receptor (CAR) sequence consisting of the V H and V L gene segments of the CD19-specific FMC63 mAb, an lgG4 hinge-C H2 -C H3 , the transmembrane and cytoplasmic signaling domains of the costimulatory molecule CD28 that contains gg mutations that enhance chimeric receptor expression and function (Nguyen et al. 2003), and the cytoplasmic domain of the ⁇ D3 ⁇ chain (Kowolik et al.
  • CAR chimeric antigen receptor
  • CD19R(L235E)28Z-T2A-EGFRt_epHIV7, CD19R(N297Q)28Z-T2A-EGFRt_epHIV7 and CD19R(EQ)28Z-T2A-EGFRt_epHIV7 vectors were generated by site directed mutagenesis using the QuikChange II XL kit (Agilent Technologies, Santa Clara, CA) of a codon optimized CD19R28Z_pGA plasmid that had been synthesized by Geneart, digested with Nhel/Rsrll and ligated with a similarly digested CD19R28Z- T2A-EGFRt_epHIV7.
  • the CD19Rch2A28Z-T2A-EGFRt_epHIV7 vector was generated from a codon optimized CD19R-HL-CH3(CO)_pMK-RQ plasmid that had been synthesized by Geneart, digested with Nhel/Rsrll and ligated with a similarly digested CD19R28Z-T2A-EGFRt_epHIV7.
  • PBMCs Human peripheral blood mononuclear cells
  • COHNMC City of Hope National Medical Center
  • T CM isolation using CD14- and CD45RA-depletion followed by CD62L-selection
  • anti- CD3/CD28 bead stimulation was then done as previously described (Wang et al. 2012).
  • transduced T cells were immunomagnetically enriched for EGFRt expression as previously described (Wang et al. 201 1 a).
  • EBV-transformed lymphoblastoid cell lines (LCL) and LCL that expressed OKT3 (LCL-OKT3) (Wang et al. 201 1 b) or ffLuc + LCL cells were cultured in RPMI 1640 (Irvine Scientific, Santa Ana, CA) supplemented with 10% heat- inactivated fetal calf serum (FCS, Hyclone, Logan, UT) 2 mM L-glutamine (Irvine Scientific), and 25 mM HEPES (Irvine Scientific).
  • ffLuc+ LCL were generated by transduction with lentiviral vector eGFP-ffluc_epHIV7 at an MOI of 20 in the presence of 5 ⁇ g/mL polybrene in 500uL medium, and subsequent purification by sorting GFP+ cells.
  • Mouse myeloma cells secreting human homeostatic IL-15 cytokine (NSO-IL15) were generated as previously described (Wang et al. 201 1 b).
  • SupB15 and K562 leukemia cell lines were grown in the corresponding ATCC recommended media.
  • mice 6-10 week old NOD/Sc/d IL-2RyC null (NSG) mice were injected intravenously (i.v.) on day 0 with 10 7 of the indicated TcM-derived cells, and intraperitoneal (i.p.) injections three times a week of 2x10 7 irradiated NS0-IL15 to provide a systemic supply of human IL-15 in vivo.
  • Peripheral blood was harvested from retro-orbital bleeds, red blood cells were lysed and cell suspensions were analyzed by flow cytometry.
  • 1 .5 x 10 6 ffL uc + LCL cells were administered i.v.
  • Chromium-release Assays 4-hour 51 Cr-release assays were performed as previously described (Stastny et al. 2007) using the indicated effector/target cell ratios.
  • CD19R+ T cells fail to engraft in NSG mice.
  • Central memory T cells (TCM) as a T cell subpopulation have been characterized as having superior engraftment potential, and thus therapeutic efficacy, after adoptive transfer (Wang et al. 201 1 b). Further evidence has shown that CAR expression on the TcM-derived cells seem to correlate with decreased in vivo persistence in an in vivo xenograft model using NSG mice.
  • HuFcyR binds CD19R+ T cells.
  • the CD19R construct includes a CD19-specific scFv derived from mouse monoclonal antibody FMC63, a human lgG4 Fc linker, human CD28 transmembrane and cytoplasmic domains, and a human CD3-zeta cytoplasmic domain. Because the CAR construct includes a portion of a human lgG4 Fc region, the propensity of FcR-mediated innate immune responses to selectively clear the CD19R/EGFRt+ cells - but not the EGFRt+ cells - was investigated.
  • CD19R mutants were generated. To further test the significance of potential FcR-mediated effects on the CAR-expressing TCM population, the CD19- specific CAR was mutated at amino acids within the lgG4 CH2 domain that may be involved with FcR binding - L235E and/or N297Q (FIG. 3a). A CD19-specific CAR with a deletion of the lgG4 CH2 domain (i.e., a deletion of the domain that contains residues 235 and 297) was also generated (FIG. 3a).
  • CD19Rch2A sequences were incorporated into separate lentiviral constructs, where they were each coordinately expressed with EGFRt from a single transcript, using the T2A ribosome skip sequence in a design similar to that described in FIG. 1 a for the non-mutated CD19R.
  • TcM-derived lines were 92-99% positive for the expected transgenes (FIG. 3b), demonstrating that the mutations do not adversely affect CAR expression.
  • none of these mutations altered the CD19 specific cytolytic potential of these TcM-derived cells in 4 hour 51 Cr-release assays (FIG. 3c).
  • huFcyR binding to CARs with mutated lgG4 spacer is impaired.
  • flow cytometric analysis was performed using various human and murine biotinylated soluble FcyRs, and PE-streptavidin (SA-PE) to detect the binding of the FcyRs to the different cell populations.
  • SA-PE PE-streptavidin
  • T cells that expressed only EGFRt were not bound by these FcyRs, and T cells that expressed either the CD19R(N297Q), CD19R(L235E) or CD19R(EQ) mutants, or the CD19Rch2A deletion all displayed significantly reduced binding to these FcyRs.
  • T cells with CD19R mutants exhibit improved in vivo engraftment and persistence.
  • 10 7 T cells expressing either the parental CD19R, the EGFRt marker alone, the CD19R(L235E), the CD19R(N297Q), the CD19R(EQ), or the CD19Rch2A were infused i.v. into NSG mice.
  • peripheral blood was assayed for CD45 + EGFRt + cell engraftment (FIG. 5).
  • Engrafted EGFRt+ cells could be detected when the T cells expressed the single mutated CD19R(L235E) or CD19R(N297Q). Further, expression of the double point-mutated CD19R(EQ) or CH2-deleted CD19Rch2A rescued T cell engraftment, as levels of CD45/EGFRt+ cells observed in these groups of mice were similar to that seen when EGFRt alone was expressed. This rescued engraftment and persistence of gene- modified cells was also observed using TCM-derived cells that were not EGFRt- enriched prior to adoptive transfer (FIG. 8).
  • T cells with CD19R mutants exhibit improved therapeutic efficacy.
  • LCL is a CD19- expressing tumor cell line that was transduced to express firefly luciferase (ffLuc) to allow for bioluminescent monitoring of in vivo tumor growth.
  • ffLuc firefly luciferase
  • CAR chimeric antigen receptor
  • an Ig Fc spacer can potentially inhibit the engraftment and/or persistence of CAR-expressing cells in NSG mouse models in a manner that correlates with FcyR binding.
  • Prevention of FcyR binding by either point mutation or deletion of the relevant sequences within the CAR Fc domain can then restore the in vivo persistence of the adoptively transferred cells to that of cells which do not express a CAR.
  • the increased in vivo persistence that is mediated by the spacer- optimized CAR then translates, into significantly improved CAR-directed anti-tumor therapy in an in vivo mouse model.
  • the mutations described herein may be extrapolated to humans and should therefore augment the persistence and therapeutic efficacy of T cells expressing IgG-spacer containing CAR in humans. Any discrepancy in CAR T cell engraftment and in vivo anti-tumor efficacy is likely impacted by the nature of the murine NSG model system. Human lgG4 has been shown to efficiently bind murine FcRs to mediate potent antibody dependent cell- mediated cytotoxicity (Isaacs et al. Steplewski et al. 1988).
  • human FcRs have the strongest affinity toward lgG1 and lgG3, and reduced affinity for lgG4 (Schroeder & Cavacini 2010; Nirula et al. 201 1 ). Additionally, given that NSG mice lack serum antibodies, FcRs expressed by their innate immune cells are unoccupied and thus have a greater potential to bind the IgG-Fc spacer within the CAR. With the exception of hypoglobulinemia cases, immunocompetent humans have high serum IgG levels of approximately 10 mg/mL (Stoop et al,. 1969), which could potentially compete for recognition of IgG-containing CARs.
  • CARs containing components of an Ig Fc spacer should incorporate modifications that prevent the FcR-mediated recognition of the cells in vivo.
  • modifications can involve either point mutations to change the amino acid sequence, or sequence deletions such as that seen with the CD19R(EQ) and CD19Rch2A constructs described herein.
  • modifications prevent the ability of FcR- expressing cells to recognize the CAR-expressing immunotherapeutic cellular product in vivo, but they might also prevent the unintentional activation of the transferred T cells and/or the host immune responses (Hombach et al. 2010), which could contribute to various unwanted side-effects of this immunotherapeutic strategy.
  • IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121 : 573-584.
  • the B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1 -specific chimeric antigen receptor.
  • NOD/SCID/gamma(c)(null) mouse an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-3182.
  • T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
  • CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66: 10995-1 1004.
  • T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and anti-tumor effects against human acute myeloid leukemia. Blood.
  • CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
  • expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
  • CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1 BB domains pilot clinical trial results.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2014/028961 2014-01-13 2014-03-14 Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use WO2015105522A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP19204610.0A EP3626748A1 (de) 2014-01-13 2014-03-14 Chimäre antigenrezeptoren (cars) mit mutationen in der fc-spacerregion und verfahren zu deren verwendung
CA2936501A CA2936501A1 (en) 2014-01-13 2014-03-14 Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
AU2014376328A AU2014376328A1 (en) 2014-01-13 2014-03-14 Chimeric antigen receptors (CARs) having mutations in the Fc spacer region and methods for their use
CN201480076612.7A CN107074957B (zh) 2014-01-13 2014-03-14 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
EP14877876.4A EP3094653B1 (de) 2014-01-13 2014-03-14 Chimäre antigenrezeptoren (cars) mit mutationen in der fc-spacerregion und verfahren zu deren verwendung
US15/111,384 US20160333108A1 (en) 2014-01-13 2014-03-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
JP2016546921A JP6560235B2 (ja) 2014-01-13 2014-03-14 Ｆｃスペーサー領域に変異を有するキメラ抗原受容体（ＣＡＲ）及びそれらの使用方法
ES14877876T ES2767423T3 (es) 2014-01-13 2014-03-14 Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
US16/221,257 US20200040096A1 (en) 2014-01-13 2018-12-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
AU2020204351A AU2020204351A1 (en) 2014-01-13 2020-06-29 Chimeric Antigen Receptors (CARs) Having Mutations in the Fc Spacer Region and Methods For Their Use
US17/510,099 US20220372164A1 (en) 2014-01-13 2021-10-25 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
AU2023203097A AU2023203097A1 (en) 2014-01-13 2023-05-17 Chimeric Antigen Receptors (Cars) Having Mutations in the Fc Spacer Region and Methods for their Use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461926881P 2014-01-13 2014-01-13
US61/926,881 2014-01-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/111,384 A-371-Of-International US20160333108A1 (en) 2014-01-13 2014-03-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
US16/221,257 Continuation US20200040096A1 (en) 2014-01-13 2018-12-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE

Publications (1)

Publication Number Publication Date
WO2015105522A1 true WO2015105522A1 (en) 2015-07-16

Family

ID=53524229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/028961 WO2015105522A1 (en) 2014-01-13 2014-03-14 Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use

Country Status (8)

Country Link
US (3) US20160333108A1 (de)
EP (2) EP3094653B1 (de)
JP (1) JP6560235B2 (de)
CN (2) CN113307880A (de)
AU (3) AU2014376328A1 (de)
CA (1) CA2936501A1 (de)
ES (1) ES2767423T3 (de)
WO (1) WO2015105522A1 (de)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106117366A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种cd19特异性嵌合抗原受体及其编码基因、应用
WO2017027291A1 (en) * 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
US9574014B2 (en) 2015-05-15 2017-02-21 City Of Hope Chimeric antigen receptor compositions
WO2017062628A1 (en) * 2015-10-06 2017-04-13 City Of Hope Chimeric antigen receptors targeted to psca
WO2017136829A1 (en) * 2016-02-05 2017-08-10 City Of Hope Administration of engineered t cells for treatment of cancers in the central nervous system
WO2017172952A1 (en) * 2016-04-01 2017-10-05 Promab Biotechnologies, Inc. Flag tagged cd19-car-t cells
WO2017214333A1 (en) * 2016-06-08 2017-12-14 Intrexon Corporation Cd33 specific chimeric antigen receptors
WO2018064626A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Adaptive chimeric antigen receptor t-cell design
KR20180037294A (ko) * 2015-08-31 2018-04-11 블루버드 바이오, 인코포레이티드. 항-시알릴 Tn 키메라 항원 수용체
JP2018531015A (ja) * 2015-10-13 2018-10-25 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ クロロトキシンドメインを含むキメラ抗原レセプター
CN109096405A (zh) * 2018-09-20 2018-12-28 杭州普略生物科技有限公司 以gd2为靶点的嵌合抗原受体及药物组合物
JP2019500894A (ja) * 2015-11-04 2019-01-17 ジェイ． プライスマン，ソール Ｈｅｒ２を標的とするキメラ抗原受容体
US10266592B2 (en) 2014-04-10 2019-04-23 Seattle Children's Hospital Drug regulated transgene expression
WO2019165116A1 (en) * 2018-02-26 2019-08-29 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
US10428305B2 (en) 2014-05-15 2019-10-01 National University Of Singapore Modified natural killer cells that express IL15 and uses thereof
US10538739B2 (en) 2013-01-28 2020-01-21 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
JP2020518591A (ja) * 2017-05-01 2020-06-25 ジュノー セラピューティクス インコーポレイテッド 細胞療法と免疫調節化合物の併用
US10703819B2 (en) * 2014-08-09 2020-07-07 The Trustees Of The University Of Pennsylvania Treatment of cancer using a CD123 chimeric antigen receptor
US20200345823A1 (en) * 2017-11-07 2020-11-05 Xiuli Wang Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car
US10844371B2 (en) * 2017-09-22 2020-11-24 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
US11028177B2 (en) 2013-02-20 2021-06-08 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US11059879B2 (en) * 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
US11058722B2 (en) 2015-03-23 2021-07-13 Autolus Limited Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain
US11116834B2 (en) 2016-10-19 2021-09-14 City Of Hope Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy
US11141436B2 (en) 2019-03-05 2021-10-12 Nkarta, Inc. Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2021212069A1 (en) * 2020-04-17 2021-10-21 City Of Hope Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies
WO2021225532A1 (en) * 2020-05-08 2021-11-11 Mahidol University A chimeric antigen receptor and modified cells carrying the receptor
WO2022056085A2 (en) 2020-09-10 2022-03-17 Mustang Bio, Inc. Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer
US11365236B2 (en) 2017-03-27 2022-06-21 Nkarta, Inc. Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
CN116121302A (zh) * 2018-09-27 2023-05-16 公益财团法人实验动物中央研究所 免疫缺陷小鼠
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US11896616B2 (en) 2017-03-27 2024-02-13 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
WO2024026107A3 (en) * 2022-07-28 2024-04-11 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
MY178233A (en) 2013-12-20 2020-10-07 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
AU2015317351B2 (en) * 2014-09-19 2020-07-02 City Of Hope Costimulatory chimeric antigen receptor T cells targeting IL3Ra2
US10821161B2 (en) * 2014-12-05 2020-11-03 City Of Hope CS1 targeted chimeric antigen receptor-modified T cells
CA3008162A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3289082A4 (de) * 2015-04-27 2018-09-12 AbVitro LLC Verfahren zur sequenzierung, bestimmung, paarung und validierung von therapeutika und krankheitsspezifischen antigenen
EP3288570A4 (de) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modifizierte stammzellen und verwendungen davon
EP3484488B1 (de) 2016-07-12 2023-08-09 Kite Pharma, Inc. Antigenbindende moleküle und verfahren zur verwendung davon
JP2019530440A (ja) 2016-09-02 2019-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
JP7407701B2 (ja) * 2017-09-06 2024-01-04 フレッド ハッチンソン キャンサー センター ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN109971722B (zh) * 2017-12-28 2023-09-01 上海细胞治疗研究院 靶向cd19且高水平稳定表达cd40抗体的car-t细胞及其用途
CN109971725B (zh) * 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
CN109971723B (zh) * 2017-12-28 2023-07-07 上海细胞治疗研究院 包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途
CN109971714B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 自表达pd-1抗体并靶向间皮素的嵌合抗原受体修饰t细胞及其用途
CN109971717B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
WO2019144095A1 (en) * 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
CN112566643A (zh) * 2018-06-12 2021-03-26 加利福尼亚大学董事会 用于治疗癌症的单链双特异性嵌合抗原受体
BR112021000914A2 (pt) * 2018-07-18 2021-04-13 Amgen Inc. Receptores quiméricos para steap1 e seus métodos de uso
CA3112195A1 (en) * 2018-09-13 2020-03-19 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
CN113784732B (zh) * 2019-05-07 2024-03-22 亘喜生物科技（上海）有限公司 靶向bcma的工程化免疫细胞及其用途
US20220202864A1 (en) * 2019-05-07 2022-06-30 Gracell Biotechnologies (Shanghai) Co., Ltd. Bcma-targeting engineered immune cell and use thereof
CN111499763A (zh) * 2020-03-31 2020-08-07 江苏省省级机关医院 一种靶向mage-a1的特异性全人源嵌合抗原受体及其应用
CN112111014A (zh) * 2020-09-22 2020-12-22 廖文强 一种抗氧化嵌合型抗原受体和免疫细胞
US20230406922A1 (en) * 2020-11-20 2023-12-21 Simcere Zaiming Pharmaceutical Co., Ltd. Humanized cd19 antibody and use thereof
AU2021402100A1 (en) * 2020-12-16 2023-07-27 Orion Corporation Chimeric antigen receptor (car) spacer modifications enhance car t cell functionality
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN117004604A (zh) * 2022-04-28 2023-11-07 南京北恒生物科技有限公司 一种ciita基因被敲除的工程化免疫细胞及其用途
CN116254230A (zh) * 2022-09-14 2023-06-13 卡瑞济(北京)生命科技有限公司 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途
CN117942275A (zh) * 2022-10-31 2024-04-30 康码（上海）生物科技有限公司 一种基于病毒阻断剂的洗手液及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100309A2 (en) * 2008-02-08 2009-08-13 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
WO2011056894A2 (en) 2009-11-03 2011-05-12 Jensen Michael C TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
WO2012031744A1 (en) * 2010-09-08 2012-03-15 Chemotherapeutisches Forschungsinstitut Chimeric antigen receptors with an optimized hinge region
WO2013123061A1 (en) * 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20130287798A1 (en) * 2000-10-18 2013-10-31 Sloan-Kettering Institute For Cancer Research Uses of monoclonial antibody 8h9

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102264A1 (en) * 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
DK3214091T3 (en) * 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
WO2012168199A1 (en) * 2011-06-06 2012-12-13 Novo Nordisk A/S Therapeutic antibodies
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130287798A1 (en) * 2000-10-18 2013-10-31 Sloan-Kettering Institute For Cancer Research Uses of monoclonial antibody 8h9
WO2009100309A2 (en) * 2008-02-08 2009-08-13 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
WO2011056894A2 (en) 2009-11-03 2011-05-12 Jensen Michael C TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
WO2012031744A1 (en) * 2010-09-08 2012-03-15 Chemotherapeutisches Forschungsinstitut Chimeric antigen receptors with an optimized hinge region
WO2013123061A1 (en) * 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof

Non-Patent Citations (62)

* Cited by examiner, † Cited by third party
Title
BERGER, C; FLOWERS, ME; WARREN, EH; RIDDELL, SR: "Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation", BLOOD, vol. 107, 2006, pages 2294 - 2302
BERGER, C; JENSEN, MC; LANSDORP, PM; GOUGH, M; ELLIOTT, C; RIDDELL, SR: "Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates", J CLIN INVEST, vol. 118, 2008, pages 294 - 305, XP055284133, DOI: doi:10.1172/JCI32103
BRENNER, MK; HESLOP, HE: "Adoptive T cell therapy of cancer", CURR OPIN IMMUNOL, vol. 22, 2010, pages 251 - 257, XP027020482
BRENTJENS RJ; DAVILA ML; RIVIERE I; PARK J; WANG X; COWELL LG; BARTIDO S; STEFANSKI J; TAYLOR C; OLSZEWSKA M: "CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia", SCI TRANSL MED., vol. 5, no. 177, 2013, pages 177, XP055234457, DOI: doi:10.1126/scitranslmed.3005930
BRENTJENS RJ; RIVIERE I; PARK JH; DAVILA ML; WANG X; STEFANSKI J; TAYLOR C; YEH R; BARTIDO S; BORQUEZ-OJEDA O: "Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias", BLOOD., vol. 118, no. 18, 2012, pages 4817 - 28, XP055169039, DOI: doi:10.1182/blood-2011-04-348540
BRENTJENS, RJ; SANTOS, E; NIKHAMIN, Y; YEH, R; MATSUSHITA, M; LA PERLE, K ET AL.: "Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts", CLIN CANCER RES, vol. 13, 2007, pages 5426 - 5435, XP055204921, DOI: doi:10.1158/1078-0432.CCR-07-0674
CARTELLIERI, M; BACHMANN, M; FELDMANN, A; BIPPES, C; STAMOVA, S; WEHNER, R ET AL.: "Chimeric antigen receptor-engineered T cells for immunotherapy of cancer", J BIOMED BIOTECHNOL, 2010, pages 956304, XP002736525, DOI: doi:10.1155/2010/956304
CIERI, N; CAMISA, B; COCCHIARELLA, F; FORCATO, M; OLIVEIRA, G; PROVASI, E ET AL.: "IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors", BLOOD, vol. 121, 2013, pages 573 - 584, XP055386326, DOI: doi:10.1182/blood-2012-05-431718
DE OLIVEIRA, SN; RYAN, C; GIANNONI, F; HARDEE, CL; TREMCINSKA, I; KATEBIAN, B ET AL.: "Modification of Hematopoietic Stem/Progenitor Cells with CD19-18 Specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy", HUM GENE THER, vol. 24, 2013, pages 824 - 839, XP055244062, DOI: doi:10.1089/hum.2012.202
EDELMAN ET AL., PROC NATL ACAD SCI USA, vol. 63, 1969, pages 78 - 85
GATTINONI, L; FINKELSTEIN, SE; KLEBANOFF, CA; ANTONY, PA; PALMER, DC; SPIESS, PJ ET AL.: "Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells", J EXP MED, vol. 202, 2005, pages 907 - 912
GATTINONI, L; LUGLI, E; JI, Y; POS, Z; PAULOS, CM; QUIGLEY, MF ET AL.: "A human memory T cell subset with stem cell-like properties", NAT MED, vol. 17, 2011, pages 1290 - 1297
GRUPP S. A.; KALOS M.; BARRETT D.; APLENC R.; PORTER D. L.; RHEINGOLD S. R. ET AL.: "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia", N. ENGL. J. MED., vol. 368, 2013, pages 1509 - 1518, XP055169041, DOI: doi:10.1056/NEJMoa1215134
GUEST, RD; HAWKINS, RE; KIRILLOVA, N; CHEADLE, EJ; ARNOLD, J; O'NEILL, A ET AL.: "The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens", J IMMUNOTHER, vol. 28, 2005, pages 203 - 211, XP008072046, DOI: doi:10.1097/01.cji.0000161397.96582.59
HASO, W; LEE, DW; SHAH, NN; STETLER-STEVENSON, M; YUAN, CM; PASTAN, IH ET AL.: "Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia", BLOOD, vol. 121, 2013, pages 1165 - 1174
HESLOP, HE; STEVENSON, FK; MOLLDREM, JJ: "Immunotherapy of hematologic malignancy", HEMATOLOGY AM SOC HEMATOL EDUC PROGRAM, 2003, pages 331 - 349
HINRICHS, CS; BORMAN, ZA; GATTINONI, L; YU, Z; BURNS, WR; HUANG, J ET AL.: "Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy", BLOOD, vol. 117, 2011, pages 808 - 814, XP055235116, DOI: doi:10.1182/blood-2010-05-286286
HOMBACH, A; HOMBACH, AA; ABKEN, H: "Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response", GENE THER, vol. 17, 2010, pages 1206 - 1213, XP002718447, DOI: doi:10.1038/gt.2010.91
HOMBACH, A; WIECZARKOWIECZ, A; MARQUARDT, T; HEUSER, C; USAI, L; POHL, C ET AL.: "Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule", J IMMUNOL, vol. 167, 2001, pages 6123 - 6131, XP055083123, DOI: doi:10.4049/jimmunol.167.11.6123
HUANG, G; YU, L; COOPER, LJ; HOLLOMON, M; HULS, H; KLEINERMAN, ES: "Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases", CANCER RES, vol. 72, 2012, pages 271 - 281
HUDECEK M ET AL., CLINICAL CANCER RESEARCH, vol. 19, no. 12, 25 April 2013 (2013-04-25), pages 3153 - 3164
HUDECEK, M; LUPO-STANGHELLINI, MT; KOSASIH, PL; SOMMERMEYER, D; ENSEN, MC; RADER, C ET AL.: "Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells", CLIN CANCER RES, vol. 19, 2013, pages 3153 - 3164, XP055177780, DOI: doi:10.1158/1078-0432.CCR-13-0330
HUDECEK, M; SCHMITT, TM; BASKAR, S; LUPO-STANGHELLINI, MT; NISHIDA, T; YAMAMOTO, TN ET AL.: "The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor", BLOOD, vol. 116, 2010, pages 4532 - 4541, XP055034816, DOI: doi:10.1182/blood-2010-05-283309
IMAI, C; MIHARA, K; ANDREANSKY, M; NICHOLSON, IC; PUI, CH; GEIGER, TL ET AL.: "Chimeric receptors with 4-1 BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia", LEUKEMIA, vol. 18, 2004, pages 676 - 684, XP002579934
ISAACS, JD; GREENWOOD, J; WALDMANN, H: "Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function", J IMMUNOL, vol. 161, 1998, pages 3862 - 3869, XP009135660
ISHIKAWA, F; YASUKAWA, M; LYONS, B; YOSHIDA, S; MIYAMOTO, T; YOSHIMOTO, G ET AL.: "Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice", BLOOD, vol. 106, 2005, pages 1565 - 1573
ITO, M; HIRAMATSU, H; KOBAYASHI, K; SUZUE, K; KAWAHATA, M; HIOKI, K ET AL.: "NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells", BLOOD, vol. 100, 2002, pages 3175 - 3182
JENSEN, MC; POPPLEWELL, L; COOPER, LJ; DIGIUSTO, D; KALOS, M; OSTBERG, JR ET AL.: "Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans", BIOL BLOOD MARROW TRANSPLANT, vol. 16, 2010, pages 1245 - 1256, XP027197777
JONNALAGADDA M ET AL., JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 1, no. 1, 7 November 2013 (2013-11-07), pages 18
JONNALAGADDA, M; BROWN, CE; CHANG, WC; OSTBERG, JR; FORMAN, SJ; JENSEN, MC: "Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy", PLOS ONE, vol. 8, 2013, pages e65519, XP055299464, DOI: doi:10.1371/journal.pone.0065519
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, UNITED STATES PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KAHLON, KS; BROWN, C; COOPER, LJ; RAUBITSCHEK, A; FORMAN, SJ; JENSEN, MC: "Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells", CANCER RES, vol. 64, 2004, pages 9160 - 9166, XP002467417, DOI: doi:10.1158/0008-5472.CAN-04-0454
KALOS, M; LEVINE, BL; PORTER, DL; KATZ, S; GRUPP, SA; BAGG, A ET AL.: "T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia", SCI TRANSL MED, vol. 3, 2011, pages 95ra73, XP002667262, DOI: doi:10.1126/scitranslmed.3002842
KEBRIAEI, P; HULS, H; JENA, B; MUNSELL, M; JACKSON, R; LEE, DA ET AL.: "Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies", HUM GENE THER, vol. 23, 2012, pages 444 - 450, XP055130799, DOI: doi:10.1089/hum.2011.167
KOCHENDERFER JN; DUDLEY ME; FELDMAN SA; WILSON WH; SPANER DE; MARIC I; STETLER-STEVENSON M; PHAN GQ; HUGHES MS; SHERRY RM: "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.", BLOOD., vol. 119, no. 12, 2012, pages 2709 - 20, XP055145503, DOI: doi:10.1182/blood-2011-10-384388
KOCHENDERFER, JN; FELDMAN, SA; ZHAO, Y; XU, H; BLACK, MA; MORGAN, RA ET AL.: "Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor", J IMMUNOTHER, vol. 32, 2009, pages 689 - 702, XP009133189
KOWOLIK, CM; TOPP, MS; GONZALEZ, S; PFEIFFER, T; OLIVARES, S; GONZALEZ, N ET AL.: "CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells", CANCER RES, vol. 66, 2006, pages 10995 - 11004, XP055044266, DOI: doi:10.1158/0008-5472.CAN-06-0160
MARDIROS ET AL.: "T cells expressing CD 123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia", BLOOD, vol. 122, no. 18, 31 October 2013 (2013-10-31), pages 3138 - 3148, XP002727946 *
MARDIROS, A; DOS SANTOS, C; MCDONALD, T; BROWN, CE; WANG, X; BUDDE, LE ET AL.: "T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and anti-tumor effects against human acute myeloid leukemia", BLOOD., 2013
MILONE, MC; FISH, JD; CARPENITO, C; CARROLL, RG; BINDER, GK; TEACHEY, D ET AL.: "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo", MOL THER, vol. 17, 2009, pages 1453 - 1464
NGUYEN, P; MOISINI, I; GEIGER, TL: "Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function", BLOOD, vol. 102, 2003, pages 4320 - 4325, XP003006607, DOI: doi:10.1182/blood-2003-04-1255
NIRULA, A; GLASER, SM; KALLED, SL; TAYLOR, FR: "What is IgG4? A review of the biology of a unique immunoglobulin subtype", CURR OPIN RHEUMATOL, vol. 23, 2011, pages 119 - 124, XP009183080, DOI: doi:10.1097/BOR.0b013e3283412fd4
OVERWIJK, WW; SCHLUNS, KS: "Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications", CLIN IMMUNOL, vol. 132, 2009, pages 153 - 165, XP026301929, DOI: doi:10.1016/j.clim.2009.03.512
REDDY, MP; KINNEY, CA; CHAIKIN, MA; PAYNE, A; FISHMAN-LOBELL; J, TSUI, P ET AL.: "Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4", J IMMUNOL, vol. 164, 2000, pages 1925 - 1933
REMINGTON: "The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
SAVOLDO, B; RAMOS, CA; LIU, E; MIMS, MP; KEATING, MJ; CARRUM, G ET AL.: "CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients", J CLIN INVEST, vol. 121, 2011, pages 1822 - 1826, XP055204919, DOI: doi:10.1172/JCI46110
SAZINSKY, SL; OTT, RG; SILVER, NW; TIDOR, B; RAVETCH, JV; WITTRUP, KD: "Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors", PROC NATL ACAD SCI U S A, vol. 105, 2008, pages 20167 - 20172, XP009143223, DOI: doi:10.1073/pnas.0809257105
SCHROEDER, HW, JR.; CAVACINI, L: "Structure and function of immunoglobulins", J ALLERGY CLIN IMMUNOL, vol. 125, 2010, pages 41 - 52
See also references of EP3094653A4
STASTNY, MJ; BROWN, CE; RUEL, C; JENSEN, MC: "Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells", J PEDIATR HEMATOL ONCOL, vol. 29, 2007, pages 669 - 677, XP009113640
STEPLEWSKI, Z; SUN, LK; SHEARMAN, CW; GHRAYEB, J; DADDONA, P; KOPROWSKI, H: "Biological activity of human-mouse IgG 1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity", PROC NATL ACAD SCI U S A, vol. 85, 1988, pages 4852 - 4856, XP001007415, DOI: doi:10.1073/pnas.85.13.4852
STOOP, JW; ZEGERS, BJ; SANDER, PC; BALLIEUX, RE: "Serum immunoglobulin levels in healthy children and adults", CLIN EXP IMMUNOL, vol. 4, 1969, pages 101 - 112
STRAATHOF ET AL.: "An inducible caspase 9 safety switch for T-cell therapy", BLOOD, vol. 105, no. 11, 1 June 2005 (2005-06-01), pages 4247 - 4254, XP008126232, DOI: doi:10.1182/blood-2004-11-4564
STROHL, WR: "Optimization of Fc-mediated effector functions of monoclonal antibodies", CURR OPIN BIOTECHNOL, vol. 20, 2009, pages 685 - 691, XP026778879, DOI: doi:10.1016/j.copbio.2009.10.011
SZYMCZAK, AL; WORKMAN, CJ; WANG, Y; VIGNALI, KM; DILIOGLOU, S; VANIN, EF ET AL.: "Correction of multi-gene deficiency in vivo using a single 'selfcleaving' 2A peptide-based retroviral vector", NAT BIOTECHNOL, vol. 22, 2004, pages 589 - 594, XP002369309, DOI: doi:10.1038/nbt957
TILL, BG; JENSEN, MC; WANG, J; QIAN, X; GOPAL, AK; MALONEY, DG ET AL.: "CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1 BB domains: pilot clinical trial results", BLOOD, vol. 119, 2012, pages 3940 - 3950, XP002771432, DOI: doi:10.1182/blood-2011-10-387969
WANG, X; BERGER, C; WONG, CW; FORMAN, SJ; RIDDELL, SR; JENSEN, MC: "Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice", BLOOD, vol. 117, 2011, pages 1888 - 1898
WANG, X; CHANG, WC; WONG, CW; COLCHER, D; SHERMAN, M; OSTBERG, JR ET AL.: "A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells", BLOOD, vol. 118, 2011, pages 1255 - 1263, XP055062819, DOI: doi:10.1182/blood-2011-02-337360
WANG, X; NARANJO, A; BROWN, CE; BAUTISTA, C; WONG, CW; CHANG, WC ET AL.: "Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale", J IMMUNOTHER, vol. 35, 2012, pages 689 - 701, XP055211902, DOI: doi:10.1097/CJI.0b013e318270dec7
WILKIE, S; PICCO, G; FOSTER, J; DAVIES, DM; JULIEN, S; COOPER, L ET AL.: "Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor", J IMMUNOL, vol. 180, 2008, pages 4901 - 4909
YANG, S; JI, Y; GATTINONI, L; ZHANG, L; YU, Z; RESTIFO, NP ET AL.: "Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails", CANCER IMMUNOL IMMUNOTHER, vol. 62, 2013, pages 727 - 736
ZHONG, XS; MATSUSHITA, M; PLOTKIN, J; RIVIERE, I; SADELAIN, M: "Chimeric antigen receptors combining 4-1 BB and CD28 signaling domains augment Pi3kinase/AKT/Bci-XL activation and CD8+ T cell-mediated tumor eradication", MOL THER, vol. 18, 2010, pages 413 - 420, XP055023623, DOI: doi:10.1038/mt.2009.210

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11873512B2 (en) 2013-01-28 2024-01-16 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
US10538739B2 (en) 2013-01-28 2020-01-21 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
US10774309B2 (en) 2013-01-28 2020-09-15 St. Jude Children's Research Hospital, Inc. Natural killer cell immunotherapy for treating cancer
US10801012B2 (en) 2013-01-28 2020-10-13 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
US10829737B2 (en) 2013-01-28 2020-11-10 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
US10836999B2 (en) 2013-01-28 2020-11-17 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
US11028177B2 (en) 2013-02-20 2021-06-08 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US10865242B2 (en) 2014-04-10 2020-12-15 Seattle Children's Hospital Method and compositions for cellular immunotherapy
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
US11155616B2 (en) 2014-04-10 2021-10-26 Seattle Children's Hospital Drug regulated transgene expression
US11414486B2 (en) 2014-04-10 2022-08-16 Seattle Children's Hospital Transgene genetic tags and methods of use
US10266592B2 (en) 2014-04-10 2019-04-23 Seattle Children's Hospital Drug regulated transgene expression
US10774311B2 (en) 2014-05-15 2020-09-15 National University Of Singapore Natural killer cells modified to express membrane-bound interleukin 15 and uses thereof
US10428305B2 (en) 2014-05-15 2019-10-01 National University Of Singapore Modified natural killer cells that express IL15 and uses thereof
US11560548B2 (en) 2014-05-15 2023-01-24 National University Of Singapore Immune cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereof
US10703819B2 (en) * 2014-08-09 2020-07-07 The Trustees Of The University Of Pennsylvania Treatment of cancer using a CD123 chimeric antigen receptor
US11591404B2 (en) 2014-08-19 2023-02-28 Novartis Ag Treatment of cancer using a CD123 chimeric antigen receptor
US11058722B2 (en) 2015-03-23 2021-07-13 Autolus Limited Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain
EP3842448A1 (de) 2015-05-15 2021-06-30 City of Hope Chimäre antigenrezeptorzusammensetzungen
US10590205B2 (en) 2015-05-15 2020-03-17 City Of Hope Chimeric antigen receptor compositions
US9574014B2 (en) 2015-05-15 2017-02-21 City Of Hope Chimeric antigen receptor compositions
US11123369B2 (en) 2015-08-07 2021-09-21 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
WO2017027291A1 (en) * 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
JP2018526028A (ja) * 2015-08-31 2018-09-13 ブルーバード バイオ， インコーポレイテッド 抗シアリルｔｎキメラ抗原受容体
US11279769B2 (en) 2015-08-31 2022-03-22 Helixmith Co., Ltd Anti-Sialyl Tn chimeric antigen receptors
KR102715016B1 (ko) * 2015-08-31 2024-10-11 주식회사 헬릭스미스 항-시알릴 Tn 키메라 항원 수용체
KR20180037294A (ko) * 2015-08-31 2018-04-11 블루버드 바이오, 인코포레이티드. 항-시알릴 Tn 키메라 항원 수용체
AU2016336515B2 (en) * 2015-10-06 2023-08-24 City Of Hope Chimeric antigen receptors targeted to PSCA
WO2017062628A1 (en) * 2015-10-06 2017-04-13 City Of Hope Chimeric antigen receptors targeted to psca
IL258502B2 (en) * 2015-10-06 2023-05-01 Hope City psca-targeted chimeric antigen receptors
CN115074331B (zh) * 2015-10-06 2024-05-17 希望之城公司 靶向psca的嵌合抗原受体
EP3747462A1 (de) * 2015-10-06 2020-12-09 City of Hope Auf psca gerichtete chimäre antigenrezeptoren
CN108290956A (zh) * 2015-10-06 2018-07-17 希望之城公司 靶向psca的嵌合抗原受体
CN115074331A (zh) * 2015-10-06 2022-09-20 希望之城公司 靶向psca的嵌合抗原受体
IL258502A (en) * 2015-10-06 2018-05-31 Hope City psca-targeted chimeric antigen receptors
CN108290956B (zh) * 2015-10-06 2022-07-05 希望之城公司 靶向psca的嵌合抗原受体
US11466097B2 (en) 2015-10-06 2022-10-11 City Of Hope Chimeric antigen receptors targeted to PSCA
JP7085990B2 (ja) 2015-10-13 2022-06-17 シティ・オブ・ホープ クロロトキシンドメインを含むキメラ抗原レセプター
US20220177528A1 (en) * 2015-10-13 2022-06-09 City Of Hope Chimeric antigen receptors containing a chlorotoxin domain
JP2022060226A (ja) * 2015-10-13 2022-04-14 シティ・オブ・ホープ クロロトキシン領域を含むキメラ抗原受容体
JP7331162B2 (ja) 2015-10-13 2023-08-22 シティ・オブ・ホープ クロロトキシン領域を含むキメラ抗原受容体
JP2018531015A (ja) * 2015-10-13 2018-10-25 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ クロロトキシンドメインを含むキメラ抗原レセプター
US11230577B2 (en) 2015-10-13 2022-01-25 City Of Hope Chimeric antigen receptors containing a chlorotoxin domain
US11059879B2 (en) * 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
JP2021192617A (ja) * 2015-11-04 2021-12-23 ジェイ． プライスマン，ソール Ｈｅｒ２を標的とするキメラ抗原受容体
JP7264954B2 (ja) 2015-11-04 2023-04-25 ジェイ． プライスマン，ソール Ｈｅｒ２を標的とするキメラ抗原受容体
EP4074731A1 (de) * 2015-11-04 2022-10-19 City of Hope Gegen her2 gerichtete chimäre antigenrezeptoren
JP2019500894A (ja) * 2015-11-04 2019-01-17 ジェイ． プライスマン，ソール Ｈｅｒ２を標的とするキメラ抗原受容体
US11197919B2 (en) 2015-11-04 2021-12-14 City Of Hope Chimeric antigen receptors targeting HER2
WO2017136829A1 (en) * 2016-02-05 2017-08-10 City Of Hope Administration of engineered t cells for treatment of cancers in the central nervous system
CN108779160A (zh) * 2016-02-05 2018-11-09 希望之城公司 施用工程化t细胞以治疗中枢神经系统中的癌症
US11034763B2 (en) 2016-04-01 2021-06-15 Promab Biotechnologies, Inc. Flag tagged CD19-CAR-T cells
WO2017172952A1 (en) * 2016-04-01 2017-10-05 Promab Biotechnologies, Inc. Flag tagged cd19-car-t cells
US11787848B2 (en) 2016-06-08 2023-10-17 Precigen, Inc. CD33 specific chimeric antigen receptors
WO2017214333A1 (en) * 2016-06-08 2017-12-14 Intrexon Corporation Cd33 specific chimeric antigen receptors
CN110191898A (zh) * 2016-06-08 2019-08-30 英特瑞克斯顿股份有限公司 Cd33特异性嵌合抗原受体
CN110191898B (zh) * 2016-06-08 2024-05-10 英特瑞克斯顿股份有限公司 Cd33特异性嵌合抗原受体
CN106117366A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种cd19特异性嵌合抗原受体及其编码基因、应用
WO2018064626A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Adaptive chimeric antigen receptor t-cell design
US11690908B2 (en) 2016-10-19 2023-07-04 City Of Hope Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy
US11116834B2 (en) 2016-10-19 2021-09-14 City Of Hope Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
US11365236B2 (en) 2017-03-27 2022-06-21 Nkarta, Inc. Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
US11896616B2 (en) 2017-03-27 2024-02-13 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
JP7299841B2 (ja) 2017-05-01 2023-06-28 ジュノー セラピューティクス インコーポレイテッド 細胞療法と免疫調節化合物の併用
JP2020518591A (ja) * 2017-05-01 2020-06-25 ジュノー セラピューティクス インコーポレイテッド 細胞療法と免疫調節化合物の併用
US11834654B2 (en) 2017-09-22 2023-12-05 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
US10844371B2 (en) * 2017-09-22 2020-11-24 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US20200345823A1 (en) * 2017-11-07 2020-11-05 Xiuli Wang Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car
JP2021514631A (ja) * 2018-02-26 2021-06-17 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための組成物および方法
WO2019165116A1 (en) * 2018-02-26 2019-08-29 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
US20210079061A1 (en) * 2018-02-26 2021-03-18 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
CN109096405B (zh) * 2018-09-20 2021-07-09 杭州普略生物科技有限公司 以gd2为靶点的嵌合抗原受体及药物组合物
CN109096405A (zh) * 2018-09-20 2018-12-28 杭州普略生物科技有限公司 以gd2为靶点的嵌合抗原受体及药物组合物
CN116121302A (zh) * 2018-09-27 2023-05-16 公益财团法人实验动物中央研究所 免疫缺陷小鼠
US11253547B2 (en) 2019-03-05 2022-02-22 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
US11154575B2 (en) 2019-03-05 2021-10-26 Nkarta, Inc. Cancer immunotherapy using CD19-directed chimeric antigen receptors
US11141436B2 (en) 2019-03-05 2021-10-12 Nkarta, Inc. Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2021212069A1 (en) * 2020-04-17 2021-10-21 City Of Hope Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies
WO2021225532A1 (en) * 2020-05-08 2021-11-11 Mahidol University A chimeric antigen receptor and modified cells carrying the receptor
WO2022056085A2 (en) 2020-09-10 2022-03-17 Mustang Bio, Inc. Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2024026107A3 (en) * 2022-07-28 2024-04-11 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof

Also Published As

Publication number Publication date
ES2767423T3 (es) 2020-06-17
AU2014376328A1 (en) 2016-07-21
AU2023203097A1 (en) 2023-06-08
CA2936501A1 (en) 2015-07-16
EP3094653B1 (de) 2019-10-23
EP3094653A1 (de) 2016-11-23
EP3094653A4 (de) 2017-08-30
US20160333108A1 (en) 2016-11-17
AU2020204351A1 (en) 2020-07-16
CN107074957A (zh) 2017-08-18
EP3626748A1 (de) 2020-03-25
US20200040096A1 (en) 2020-02-06
CN113307880A (zh) 2021-08-27
JP6560235B2 (ja) 2019-08-14
US20220372164A1 (en) 2022-11-24
JP2017507919A (ja) 2017-03-23
CN107074957B (zh) 2021-05-07

Similar Documents

Publication Publication Date Title
US20220372164A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
US11918606B2 (en) CD123-specific chimeric antigen receptor redirected t cells and methods of their use
TW201617369A (zh) 能夠結合cd19和cd3的雙特異性單價雙抗體及其用途
JP2024116283A (ja) Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤
WO2020089437A1 (en) Combination therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14877876

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2936501

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016546921

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15111384

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014376328

Country of ref document: AU

Date of ref document: 20140314

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014877876

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014877876

Country of ref document: EP